Cart
sales@molnova.com
NSC45586
CAS No. 6300-44-3
NSC45586( —— )
Catalog No. M24634 CAS No. 6300-44-3
NSC45586 is a protein phosphatase PHLPP inhibitor, which is selective for PHLPP1 and PHLPP2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 55 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 129 | In Stock |
|
| 25MG | 219 | In Stock |
|
| 50MG | 327 | In Stock |
|
| 100MG | 520 | In Stock |
|
| 500MG | 1107 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNSC45586
-
NoteResearch use only, not for human use.
-
Brief DescriptionNSC45586 is a protein phosphatase PHLPP inhibitor, which is selective for PHLPP1 and PHLPP2.
-
DescriptionNSC45586 is a protein phosphatase PHLPP inhibitor, which is selective for PHLPP1 and PHLPP2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPHLPP1|PHLPP2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6300-44-3
-
Formula Weight413.4
-
Molecular FormulaC20H18N6NaO3+
-
Purity>98% (HPLC)
-
SolubilityDMSO:82 mg/mL;Water:Insoluble;Ethanol:Insoluble
-
SMILESCC1=CC(=C(C=C1N)N)N=NC2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O.[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jackson T C , Verrier J D , Drabek T , et al. Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes.[J]. Journal of Pharmacology and Experimental Therapeutics, 2013, 347(2):516-528.
molnova catalog
related products
-
[Nle4] a-MSH, amide
[Nle4] a-MSH, amide
-
IXA6
IXA6, a novel IRE1/XBP1s agonist with potential vasoprotective activity, activates IRE1-XBP1s signaling and XBP1s transcriptional response, making it useful for studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
-
Memantine
Memantine, an amantadine derivative with some dopaminergic effects, has been proposed as an antiparkinson agent and has may be used to treat moderate to severe Alzheimer's disease. It acts on the glutamatergic system by blocking NMDA receptors.
